Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial

Alessandro Pacchiarotti; Marco Sbracia; Antonio Frega; Helmy Selman; Leonardo Rinaldi; Arianna Pacchiarotti

doi:10.1016/j.fertnstert.2010.04.035

Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial

Fertil Steril. 2010 Nov;94(6):2467-9. doi: 10.1016/j.fertnstert.2010.04.035. Epub 2010 May 26.

Authors

Alessandro Pacchiarotti¹, Marco Sbracia, Antonio Frega, Helmy Selman, Leonardo Rinaldi, Arianna Pacchiarotti

Affiliation

¹ Praxi Pro Vita IVF Center of Roma, Rome, Italy.

PMID: 20537626
DOI: 10.1016/j.fertnstert.2010.04.035

Abstract

To compare IVF outcome in ovarian stimulation protocols with recombinant FSH plus recombinant LH versus hMG, 122 patients were randomized into two study groups: group A, patients treated with urinary hMG, and group B, patients treated with rFSH plus rLH. The two groups proved to be comparable to the main IVF outcome (pregnancy rate, implantation rate, oocytes, and embryos quality), with an increasing risk of ovarian hyperstimulation in the Pergoveris group.

Publication types

Multicenter Study
Randomized Controlled Trial

MeSH terms

Drug Combinations
Female
Fertility Agents, Female / administration & dosage
Fertilization in Vitro*
Follicle Stimulating Hormone / administration & dosage*
Humans
Infertility / therapy*
Luteinizing Hormone / administration & dosage*
Male
Menotropins / administration & dosage*
Ovulation Induction / methods
Pregnancy
Pregnancy Rate
Recombinant Proteins / administration & dosage

Substances

Drug Combinations
Fertility Agents, Female
Recombinant Proteins
pergoveris
Menotropins
Luteinizing Hormone
Follicle Stimulating Hormone